The 2014 Calendar year report covers 2013 diagnosed cases.
The Holden Comprehensive Cancer Center (HCCC) Oncology Registry is committed to collecting and providing information on all cancer patients diagnosed and/or treated at the University of Iowa Hospitals and Clinics.
The HCCC is a National Cancer Institute (NCI) designated Comprehensive Cancer Center which includes a wide range of multidisciplinary cancer care programs. The HCCC Oncology Registry is also approved by the American College of Surgeons Commission on Cancer (ACoS CoC) as an Approved Cancer Program. The UIHC was surveyed by the ACoS CoC in the last quarter of 2008 and obtained the "Outstanding Achievement Award," reserved for facilities that strive for excellence in providing quality care to their cancer patients. To obtain this level of recognition, facilities must receive a commendation rating in all 9 defined areas and receive compliance rating for all other 27 standards.
The HCCC Oncology Registry has data available from 1938 to present for medical staff to analyze and utilize to enhance and improve patient care. Data is abstracted from the patient’s medical record within 6 months of initial diagnosis and includes such information as: demographics, stage of disease (at diagnosis), Collaborative Staging, first course treatment information, cancer status and vital status; all as required by the ACoS CoC. Collaborative Staging is a carefully selected set of numerous data items that describe how far a cancer has spread at the time of diagnosis
The HCCC Oncology Registry accessions all inpatients and outpatients with malignant disease and all benign and borderline primary tumors of the brain and central nervous system (CNS) who are initially diagnosed and/or treated at UI Hospitals and Clinics [analytic] and for patients that present with persistent, recurrent and/or metastatic disease that receive treatment at UI Hospitals and Clinics; included are patients that are diagnosed at autopsy [non-analytic]. All data represented in this report include only analytic cases, unless otherwise specified.
Annual follow-up of patients is one of the important functions of the HCCC Oncology Registry. Follow-up is conducted for the lifetime of the patient. Most recent calculations reveal a 99% success rate on all cases diagnosed within the past 5 years and a 99% success rate for patients diagnosed since reference date. The rate required by the ACoS CoC is 90% and 80% respectively. The HCCC Oncology Registry has historically surpassed these ACoS CoC requirements.
Follow-up is automatically collected on all patients (both analytic and non-analytic) who return to the UI Hospitals and Clinics. UI Hospitals and Clinics sends out follow-up questionnaires to all patients, family and/or physician who have not returned to the UI Hospitals and Clinics in the past year, making telephone contacts as necessary.
The HCCC submits data annually to two National Cancer Databases; 1) -- the National Cancer Institute Surveillance, Epidemiology and End Results (NCI SEER) via the Iowa Cancer Registry and 2) -- The American College of Surgeons National Cancer Database (NCDB). State laws require reporting of cancer.
The HCCC Activity Report will focus on lung and prostate analytic cancers; accounting for more than 18% of the total analytic cases seen at the UIHC this past year. The leading 5 sites are: Lung, Prostate, Endometrium, Breast and Benign Brain.